Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities Webcast (2025)

This course is intended for practicing urologists, residents, fellows, and APPs interested in optimizing detection, staging, and follow-up of genitourinary malignancies through the use of molecular imaging opportunities. The attendee will explore current diagnostic imaging modalities, their performance characteristics, and imaging guidelines for cancer staging. This will lead into an introduction of novel molecular imaging tests and their clinical applications. Emphasis will be placed on novel PET radiopharmaceutical agents in combination with CT or MRI for prostate (FDG, Choline, Acetate, NaF, FACBC, PSMA), kidney (FDG, Sestamibi, carbonic anhydrase), bladder (FDG, Choline, Acetate, fibroblast activation protein) as well as testis cancer (FDG). Differences among the imaging modalities and how they compare to existing diagnostic tests will be highlighted. Discussions will focus on practical case-based examples and integration into clinical practice. At the end of this course, participants should be able to independently determine the strengths and limitations of emerging molecular imaging modalities in urologic oncology. This multidisciplinary course led by a combination of urologists, nuclear medicine experts, and medical oncologists, will be conducted through a hybrid approach of lectures and attendee participation.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC,  Lantheus Medical Imaging,  Novartis Pharmaceuticals Corporation, Pfizer, Inc. 

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.
  2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images
  3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.
  4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.
  5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
  6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/07/2025
Course expires: 
05/07/2026
Part of: 
AUA2025 Instructional Course Webcasts
Rating: 
0

FACULTY DISCLOSURES

NameCompany NameRelationship TypeEnd Date
Behr, SpencerNovartisConsultant or AdvisorCurrent
Bjurlin, Marc ATelix PharmaceuticalsConsultant or AdvisorCurrent
Gorin, Michael A.Lantheus Medical Imaging, Inc.Other-Speakers bureau Current
Rose, TracyNo relevant financial relationships to disclose

EDUCATION COUNCIL DISCLOSURE

PDF icon Education Council Disclosures_June 2024.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF icon COI Review Workgroup Disclosures_June 2024.pdf

 

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2025
Expiration Date: May, 2026

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.